Avid Bioservices Inc (CDMO)

[cjgaddy]

The names of 3 New Bavi Trials (incl. AZN/Durvalumab & BMS/Opdivo) may well be these once they appear on https://www.clinicaltrials.gov . We'll see!

From: http://adisinsight.springer.com/search – updated 9-9-15:

“Phase I/Ib trial of bavituximab in combination with durvalumab in patients with multiple solid tumors”
PLANNING
Drugs: Bavituximab (Primary)
[Note: Durvalumab = AstraZeneca's anti-PD-L1 mab, aka MEDI4736]
Indications: Solid tumors
Phase of Trial: Phase I

“An open-label multi-center, randomized Phase II trial of the anti-PD-1 monoclonal antibody nivolumab (Opdivo) versus nivolumab plus bavituximab in patients with previously treated locally advanced or metastatic NSCLC”
PLANNING
Drugs: Bavituximab (Primary); Nivolumab
[Note: Opdivo(nivolumab) = Bristol-Myers Squibb's anti-PD-1 mab]
Indications: Non-small cell lung cancer
Phase of Trial: Phase II

“A phase II/III open-label trial of physician's choice of either docetaxel or paclitaxel with or without bavituximab in patients with locally advanced or metastatic HER2 negative breast cancer”
Planning
Drugs: Bavituximab (Primary)
Indications: Breast cancer
Phase of Trial: Phase II/III

= = = = = = = = = = = = = = = = =To The Best of My Knowledge:
9-2015 UPCOMING NEW BAVI TRIALS (per Dr.Hutchins 8-26-15/ImVacS & 9-9-15/CC) http://tinyurl.com/qz64pzg
...Ph.2 (PPHM 1501), Bavi+Optivo(nivolumab), 2ndLine NSCLC, squam+nonsquam (randomized, open-label)
...Ph.2/3 (PPHM 1502), Bavi+Paclitaxel-or-Docetaxel(Dr’sChoice), Early-Stage Her2- Breast Cancer
...Ph.2/3 (PPHM 1401), Bavi+neoadjuvant-paclitaxel, Her2- Met. Breast Cancer
6-1-15 New Bavi Trials planned: Ph2 Bavi+Opdivo/2L-NSCLC(Squamous+NonSquamous), Ph2/3 Bavi+Doce/PAC/Her2-Breast http://tinyurl.com/qxu4w2x





9-9-15 Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”